Study details
Enrolling now
PSMA or FACBC PET/CT Site-Directed Therapy for Prostate Cancer
University of Washington
NCT IDNCT04175431ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 13 years
Ages
18+
Sex
Male only
Locations
2 sites in PA, WA
What this study is about
This trial is testing if PSMA or fluciclovine PET/CT site-directed therapy works to treat prostate cancer. This treatment may help detect prostate cancer early and show whether patients benefit from targeted treatment based on PET scans.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Radiation Therapy
- 2.Take Abiraterone
- 3.Take Abiraterone Acetate
- +3 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
OralOral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
abiraterone, Antineoplastic Agent [TC] (Cytochrome P450 17A1 Inhibitors), prednisone
Drug routes
oral
Endpoints
Secondary: Overall survival
Procedures
imaging, radiation